Tofersen approved by the MHRA to treat rare inherited form of motor neurone disease

Professor Henrietta Hughes reflects on how MHRA strategy must prioritise patient safety via listening to lived experiences, fostering collaboration & innovation.

List of Field Safety Notices from 23-27 February 2026.

Understanding gut microbiome interactions with medicines could help explain differences in how people respond to treatment and build on existing medicine safety knowledge to support safer, more effective prescribing in the future.

The internationally renowned expert in the calculation and communication of risk and statistics, Sir David Spiegelhalter, discusses the concept of a ‘preference zone’ to frame the demands of safety, efficacy and choice in the era of personalised medicine.

The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and
tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that it was necessary to strengthen these warnings in the product information and on packaging to better inform healthcare professionals and patients of these known risks.

Guidance for manufacturers of coronary stents. It outlines specific scenarios that should be considered when determining if an incident is reportable.